×
-0.00187675946199558 -0.00187675946199558 -0.000625586487331749 -0.000625586487331749 0.00218955270566157 -0.000625586487331749 1.11126483540835E-16 1.11126483540835E-16
Stockreport

Relypsa Announces Phase 4 Study Shows Veltassa® Demonstrated Similar Efficacy and Safety Whether Given With or Without Food in Patients with Hyperkalemia

RELYPSA (RLYP)  More Company Research Source: GlobeNewswire
PDF REDWOOD CITY, Calif., Aug. 30, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the Phase 4 TOURMALINE study, which compared the efficacy and safety of Veltassa® (patiromer) for oral suspension given with or without food for the treatment of hyperkalemia, met its primary endpoint. Results showed no statistically significant difference in the percent of patients achieving either week 3 or week 4 serum potassium in the target range (3.8 - 5.0 mEq/L) between the group taking Veltassa with food and that taking it without. Adverse events with Veltassa in this study were consistent with previous clinical trials. Data from the TOURMALINE study will be submitted for presentation at a future medical meeting and shared with the U.S. Food and Drug Administration (FDA). “In clinical studies supporting its approval, Veltassa was administered with food and its prescribing information requires Veltassa be taken with food,” said Lance Berman, [Read more]

IMPACT SNAPSHOT EVENT TIME: RLYP
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS